Verifarma announces its strategic partnership with MTIP to accelerate its global expansion in pharmaceutical technology

Today marks a key milestone in Verifarma’s history: we are announcing our strategic partnership with MTIP, a European fund specialized in healthcare technology.

A new step in our company’s evolution

At Verifarma, we continue to move forward in our commitment to transforming the pharmaceutical industry through technology.

Today, we announce a strategic investment from MTIP, a fund that supports companies with high growth potential and a strong focus on innovation.

This agreement marks the beginning of a new phase for our company, aimed at accelerating our technological development and expanding our global presence.

Sustained growth and global positioning

Founded in 2007, Verifarma has established itself as a reliable, growing, and profitable SaaS provider, currently supporting more than 2,000 companies across 26 countries.

We hold a leading position in Latin America and an expanding presence in Europe, working alongside laboratories, distributors, and industry organizations to meet global pharmaceutical traceability requirements.

Our platform enables end-to-end management of the pharmaceutical supply chain—from production to regulatory reporting—ensuring the safety and authenticity of medicines worldwide, in alignment with international standards such as GS1 Healthcare.

An evolving integrated platform

Verifarma’s ecosystem of solutions includes:

• Traceability and serialization (Track & Trace)
• Quality management (eQMS)
• Regulatory compliance
• Pharmacovigilance

In particular, our quality management solutions (eQMS) represent a strategic and growing component of our value proposition, supporting organizations in the digitalization and optimization of their processes.

A partnership to drive the next stage of growth

MTIP joins as a strategic investor, partnering with Verifarma’s founding team—led by CEO Santiago Spector Mentasti—who will continue to lead the company.

This partnership will enable us to:

• Further strengthen our traceability platform
• Scale our quality management (eQMS) capabilities
• Accelerate the development of AI-based solutions
• Expand our presence in Europe and new markets
• Continue investing in our global customer base

Beyond capital, this partnership brings valuable expertise in scaling technology companies within the healthcare sector.

Looking ahead

This partnership represents much more than an investment: it validates the path we have been building and provides an opportunity to accelerate our long-term vision.

At Verifarma, we remain focused on a clear goal: supporting the pharmaceutical industry in its challenges related to traceability, quality, and compliance—helping ensure the safety of medicines worldwide.

‍

‍